Missouri is currently home to 2009 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Shared-Decision Making for Hydroxyurea
NCT03442114
Recruiting
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences). The study will compare two methods to help clinicians facilitate this-a clinician pocket guide and a clinician hydroxyurea shared decision making toolkit-in a group of parents of children ages 0-5 with sickle cell disease. The investigators hope t... Read More
Gender:
All
Ages:
Between 1 month and 5 years
Trial Updated:
02/09/2022
Locations: The Washington University, Saint Louis, Missouri
Conditions: Sickle Cell Anemia, Children, Only
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Lymphangioleiomyomatosis
Register for Updates
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
NCT05037097
Recruiting
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
11/10/2021
Locations: Arcturus Investigational Site 201, Kansas City, Missouri
Conditions: COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
Register for Updates
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
NCT05025735
Recruiting
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC. The objective of this study is to determine if the addition of dapagliflozin to the combination of alpelisib and fulvestrant leads to significant reduction in all-grade hyperglycemia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Saint Luke's Cancer Institute, Kansas City, Missouri
Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Diabetes
Register for Updates
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Recruiting
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri
Conditions: Relapsed Refractory Multiple Myeloma
Register for Updates
Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch
NCT04624867
Recruiting
A randomized, evaluator-blinded study to assess skin irritation and skin sensitization of HP-1050 transdermal system (HP-1050) in comparison to XULANE patch in healthy female volunteers.
Gender:
Female
Ages:
Between 18 years and 35 years
Trial Updated:
08/31/2021
Locations: QPS Missouri, Springfield, Missouri
Conditions: Cumulative Irritation and Sensitization
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Early PKD Observational Cohort Study
NCT02936791
Recruiting
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being develop... Read More
Gender:
All
Ages:
Between 4 years and 35 years
Trial Updated:
05/06/2021
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Polycystic Kidney Disease
Register for Updates
The Effect of an Individualized Impairment-based, Orthopedic Physical Therapy Intervention (IOI), on Muscle Stiffness, Pelvic Floor Function, and Pain in Women With Chronic Pelvic Pain
NCT04851730
Recruiting
The primary purpose of this study is to establish if an individualized, impairment-based orthopedic intervention (IOI) can improve pelvic floor function and pain in women with Chronic Pelvic Pain (CPP). Dry needling will be used as a part of the IOI to intervene upon peripheral muscles stiffness previously found to be more stiff in this population compared to healthy controls. This study is intended to initiate a line of research aimed at assessing widely used orthopedic physical therapy practic... Read More
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
04/17/2021
Locations: Empower Your Pelvis, Lee's Summit, Missouri
Conditions: Pelvic Pain, Chronic Pain, Muscle Tightness
Register for Updates
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04816578
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: Midamerica Cancer Care, Kansas City, Missouri
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Register for Updates
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04718818
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Saint Louis, Missouri
Conditions: Ulcerative Colitis
Register for Updates